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Purpose/Objective: The aim of this study was to test the 
feasibility of deformable image registration (DIR) of the 
planning CT to MVCT taken during treatment for calculation 
of the dose of the day for head and neck (HN) patients.  
Materials and Methods: kVCT/MVCT images of six HN 
patients treated with Helical Tomotherapy (HT) with a 
simultaneous integrated boost (54/66/69 Gy/30 fr) were 
retrospectively analyzed. For each patient the planning kVCT 
(CT-plan) was elastically registered (DIR) to the MVCT 
acquired at the 15th therapy session (MVCT15) with a B-Spline 
deformation algorithm using Mattes mutual information 
(open-source software 3D Slicer), resulting in a deformed CT 
(CTdef). At the same day of MVCT15, a kVCT was acquired 
with the patient in the same treatment position (CT15) and 
taken as reference for the calculation of the dose of the day. 
Then, CTdef and CT15 were re-sampled to the same slice 
thickness (3mm) through linear interpolation. The original HT 
plans were recalculated both on CTdef and CT15 in the HT 
planning station using the DQA (dose quality assurance) 
module, considering the two set of images as phantoms: 
images were rigidly aligned with the CT-plan, mimicking the 
true daily repositioning. Dose distributions on CTdef and 
CT15 were compared in order to assess the reliability of the 
method; local dose differences <2% of the prescribed dose 
(DD2%) and global gamma-index values (2%-2mm; considering 
points with dose >20% of the prescribed one) were assessed 
for all the available transversal slices (step: 6 mm) with 
Mapcheck SNC Patient Software (Sun Nuclear).  
Results: The results of DIR was qualitatively satisfactory 
when comparing CTdef against CT15. Twenty-nine slices for 
each patient (range: 20 – 47) were on average available for 
the evaluation of local dose differences and gamma analysis. 
On average, 93.0% ± 1.2% of points passes the gamma analysis 
test and 86% ±2% of the body ‘s voxel were found for DD2%. A 
slight improvement was found when excluding the first/last 
slices near the treatment FOV (respectively 94.4% ± 1.4% for 
gamma and 88% ± 2% for DD2%). Excluding one patient where 
a significant number of slices were cut due to the narrow FOV 
of the MVCT15, the values further improved to 95.2% ± 1.4% 
and 89% ± 2% for gamma and DD2% respectively. 
Conclusions: CT to MVCT DIR using an open source system 
was proven to be an accurate method for calculating the 
dose of the day in HT treatments for HN cancer and a reliable 
tool for the implementation of adaptive Tomotherapy 
strategies. 
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Purpose/Objective: Automated decision-making for adaptive 
radiotherapy for lung cancer patients is increasingly 
important with dose escalation strategies and modern 
radiotherapy techniques such as volumetric modulated arc 
therapy (VMAT). It is known that anatomical changes 
requiring adaptive radiotherapy occur frequently (~20%) in 
lung cancer patients. The aim of this study was to investigate 
whether EPID dosimetry, more specifically integrated transit 
planar dosimetry (ITPD), was able to detect the dose 
discrepancies caused by these anatomy changes and could be 
used for informed decision making for adaptive radiotherapy. 
The hypothesis was that 'gross' changes, now only caught 
indirectly by qualitative visual inspection of the kiloVoltage 
ConeBeam CT (kV-CBCT) images, could be detected 
automatically by using ITPD. 
Materials and Methods: For this study 60 lung cancer 
patients who underwent treatment adaptation in routine 
clinical practice were analyzed with ITPD. In this simulation 
study, a reference ITPD was predicted using the original 
planning CT and the original treatment plan. This was then 
compared to a second predicted ITPD of the original 
treatment plan on a later acquired planning CT, right before 
treatment adaptation. A global γ-evaluation with dose 
difference and distance-to-agreement criteria of 3% and 3mm 
was performed and the percentage pixels exceeding unity 
within the field shape P(γ>1) was scored for each beam. For 
all patients, the 3D dose was calculated on the original 
treatment plan and was also recalculated on the later 
planning CT with its new delineation. The planning target 
volume (PTV) coverage was compared between both 3D dose 
distributions to quantitatively confirm that treatment 
adaptation was necessary. 
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Results: In 3 out of the first 4 cases, ITPD detected EPID dose 
differences due to anatomical changes. The figure shows an 
example case (A) of ITPD detecting the anatomical change. 
The table shows P(γ>1) for the first 4 patients.  
 
 
 
 
Conclusions: Our simulations show that when ITPD is 
implemented clinically, it can automatically detect 'gross' 
anatomical changes occurring during the course of (chemo-) 
radiotherapy in lung cancer patients, which can be used as a 
trigger for adaptive radiotherapy. Only patients were 
analyzed who underwent treatment adaptation based on 
visually detected anatomic differences.  
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Purpose/Objective: To establish the optimal planning risk 
volume (PRV) to the lenses for nasal cavity and paranasal 
sinus cancer patients during image guided intensity 
modulated radiation therapy (IG-IMRT). 
Materials and Methods: Geometrical uncertainties of the 
lenses were evaluated for retrospective group (RG) of 
patients for whom PRV for lenses was not applied. 
Differences between planned and delivered maximum doses 
to the lenses were established for every fraction dose and for 
cumulative dose. Maximum doses were evaluated as a dose 
received by 0.02 cm3 of the lenses. Finally, relations between 
dose differences and geometrical uncertainties were analysed 
to establish an optimal PRV for the lenses. The PRV was 
calculated according to the formula: 1.3 × Σ + 0.5 × σ 
(McKenzie A, et al. Radiother Oncol 2002). Obtained results 
were evaluated in the prospective group (PG) of patients for 
whom calculated PRV was applied. 
Results: Retrospective study (RG) based on the 330 
observations from 10 nasal cavity and paranasal sinus cancer 
patients. The average shifts of the lenses have not got any 
dominant directionality, and were lower than 1 mm for each 
direction. Nevertheless, intra-patient analysis shows large 
variation of the lenses position during IG-IMRT. The 
systematic and random errors equaled respectively: 0.6 mm 
and 2.3 mm in R-L direction; 0.8 mm and 1.6 mm in C-C 
direction; and 0.4 mm and 1.5 mm in A-P direction.  
The differences between planned and delivered doses have 
normal distribution (p=0.542, Shapiro-Wilk's test). High 
mobility of the lenses leads to the fact that only for 11.1% 
observations, the differences between planned and delivered 
doses are lower than 3%. The delivered doses were: higher 
than planned by 10% for 40.7% of observations; higher than 
30% for 16.7 % of observations; and higher than 50% for 5.6% 
of observations. The calculated margins were respectively: 
1.9 mm in R-L direction; 1.8 mm in C-C direction, and 1.3 
mm in A-P direction. As a result, clinical PRV for lenses was 
established on 2 mm. To evaluate applied margin, an analysis 
of dose distributions for 10 prospectively treated patients 
(PG) was done. The dose distribution in planning target 
volume for the RG (without PRV) and for the PG (2 mm PRV 
for lenses) was comparable (p=0.122, Mann-Whitney test). 
The differences between planned and delivered doses in 
lenses were significantly smaller for PG (p=0.013, 
Kolmogorov-Smirnov test). For PG the delivered doses were: 
higher than planned by 10% for 17.4% of observations; higher 
than 30% for 3.3 % of observations; and higher than 50% for 
0.8% of observations. 
Conclusions: Our study showed that for radiation therapy of 
nasal cavity and paranasal sinus cancer, the planning risk 
volume for the lenses could be defined as 2 mm. This margin 
does not affect on the dose distribution in planning target 
volume and effectively reduce the differences between 
planned doses and delivered doses in lenses.  
